Steatotic liver disease classification is dynamic, affecting clinical trial eligibility and subclass-specific treatments

Hepatology

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

Hepatology

Ng WH, Yeo YH, Kim H, Seki E, Rees J, Ma KS, Moylan CA, Rodriquez LM, Abdelmalek M, Villanueva A, Noureddin M, Yang JD

doi: 10.1097/HEP.0000000000001333

Hepatology

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

Gastroenterology

Liu WY, Huang S, Ji H, Kim SU, Cheuk-Fung Yip T, Lai-Hung Wong G, Petta S, Tsochatzis E, Nakajima A, Bugianesi E, George Goh BB, Chan WK, Romero-Gomez M, Sanyal AJ, Boursier J, Hagström H, Calleja JL, de Lédinghen V, Newsome PN, Fan JG, Lai M, Castéra L, Lee HW, Pennisi G, Yoneda M, Armandi A, Kim-Jun Teh K, Gallego-Durán R, Asgharpour A, de Saint-Loup M, Shang Y, Llop E, Fournier C, Mahgoub S, Lara-Romero C, Canivet CM, Sau-Wai Chan M, Lin H, Chen LL, Targher G, Byrne CD, Du M, Wai-Sun Wong V, Zheng MH, VCTE-Prognosis Study Group

doi: 10.1053/j.gastro.2025.02.034

HepatologyFurther Publications

All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease

J Hepatol

Huang SC, Su TH, Tseng TC, Hsu SJ, Hong CM, Lan TY, Liu CH, Yang HC, Liu CJ, Kao JH

doi: 10.1016/j.jhep.2024.12.009

Hepatology

The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic dysfunction-associated steatotic liver disease

BMC Gastroenterol

Amirkhizi F, Taghizadeh M, Khalese-Ranjbar B, Hamedi-Shahraki S, Asghari S

doi: 10.1186/s12876-025-03613-8

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

Hepatology

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Lancet Gastroenterol Hepatol

Mikkelsen ACD, Kjærgaard K, Schapira AHV, Mookerjee RP, Thomsen KL

doi: 10.1016/S2468-1253(24)00320-0

Further Publications

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Lancet Gastroenterol Hepatol

Lindfors A, Strandberg R, Hagström H

doi: 10.1016/S2468-1253(24)00313-3

Further Publications

Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment

Clin Gastroenterol Hepatol

Panaccione R, Ferrante M, Dotan I, Panés J, Hisamatsu T, Bossuyt P, Danese S, Song A, Kalabic J, Joshi N, Zambrano J, Zhang Y, Duan WR, Kligys K, Dubinsky MC, Lindsay JO, Vermeire S, Siegmund B, Irving PM, D'Haens G

doi: 10.1016/j.cgh.2024.12.023

Hepatology

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease

Am J Gastroenterol

Kim WR, Mannalithara A, Charu V, Chung N, Kwong A, Kwo PY, Torok NJ, Asch SM, Kim SH

doi: 10.14309/ajg.0000000000003268

Related content

Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data

From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients with Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease from A Dynamic Perspective

All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease

The clinical value of serum sirtuin-1 concentration in the diagnosis of metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

The liver-brain axis in metabolic dysfunction-associated steatotic liver disease

Screening for advanced liver fibrosis due to metabolic dysfunction-associated steatotic liver disease alongside retina scanning in people with type 2 diabetes: a cross-sectional study

Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment

Optimal population screening strategies for liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease